Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call Transcript
Operator: Hello, everyone. Thank you for joining us, and welcome to the Arcus Biosciences, Inc. First Quarter 2026 Business Update and Financial Results.
Arcus Biosciences Inc. (RCUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 2,190,404 | $47,312,724 | +13% | 0.02% |
| 2. | Bayforest Capital Theodoros Tsagaris | 8,767 | $189,367 | +11% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 20,000 | $201,200.00 | 28,400 | 2025-02-27 | Filing | |
| $10.18 | 19,800 | $201,465.00 | 2,554,160 | 2025-02-27 | Filing | |
| $11.00 | 1,363,636 | $14,999,996.00 | 31,424,760 | 2025-02-18 | Filing | |
| $21.00 | 15,238,095 | $319,999,995.00 | 30,061,124 | 2024-01-29 | Filing | |
| $19.26 | 1,010,000 | $19,452,600.00 | 14,823,029 | 2023-06-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.20 | 100 | $2,320.00 | 922,240 | 2026-01-05 | Filing | |
| $22.34 | 2,053 | $45,864.02 | 922,340 | 2026-01-05 | Filing | |
| $21.34 | 29,670 | $633,157.80 | 924,393 | 2026-01-05 | Filing | |
| $23.38 | 6,552 | $153,185.76 | 67,924 | 2025-12-31 | Filing | |
| $22.16 | 6,810 | $150,906.20 | 124,734 | 2025-12-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,424,760 | $678,774,816 | 32.05% | |
| 2. | 4,272,056 | $92,276,410 | 0% | |
| 3. | 3,856,725 | $83,305,260 | 0% | |
| 4. | 1,426,223 | $30,801,780 | 0.01% | |
| 5. | 790,613 | $17,077,241 | 0.09% |
News See All
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2025 Earnings Call Transcript
Operator: Hello, everyone, and thank you for joining the Arcus Biosciences Full Year and Fourth Quarter 2025 Earnings and Financial Results Call.
Here's What Analysts Think About Arcus Biosciences (RCUS)
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials
Arcus Biosciences Inc. (NYSE:RCUS) is one of billionaire Steve Cohen’s 10 small-cap stock picks with huge upside potential. On October 6, Arcus Biosciences Inc.
Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
Known for speed, agility, and a high-risk, high-reward investment approach, Steve Cohen is one of the most successful hedge fund managers on Wall Street.
Jim Cramer Shed Light on These 14 Stocks
“Right now, it is a wild chase, a mad dash so to speak, to make money wherever it can be found, IPOs, mergers and acquisitions, giant upside surprises.
Arcus Biosciences' Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA
Arcus Biosciences Inc. (NYSE:RCUS) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Hedge Fund Resource Center